You're contacting media contact of this press release

Title: Neuralia TMS Extends Depression Treatment Access for Australian Patients

Australia, 23rd Jul 2026 - Neuralia TMS, a prominent provider of Transcranial Magnetic Stimulation (TMS) therapy based in Como, Western Australia, has announced an extension of treatment access for patients across Australia seeking non-invasive, drug-free options for managing depression. The extension centres on the clinic's combined delivery model, which pairs in-clinic TMS sessions with at-home transcranial Direct Current Stimulation (tDCS) therapy and pharmacogenetic testing, reducing the need for patients outside the Perth metropolitan area to travel for ongoing care. The development is relevant to patients in regional and interstate locations who have previously faced logistical barriers to accessing structured mental health treatment, and reflects broader industry attention on making evidence-based, non-drug therapies available beyond major metropolitan clinics.TMS therapy uses magnetic fields to stimulate nerve cells in regions of the brain associated with mood regulation, and is offered as an alternative for patients who have not responded to standard approaches such as medication or talking therapies. The therapy has been the subject of more than three decades of clinical research and is listed under Medicare for treatment-resistant depression, a status that has applied since November 2021, and is delivered at Neuralia TMS's Como facility under the oversight of its clinical team. Patients typically begin with an initial clinical assessment before a course of sessions is scheduled, with progress reviewed at regular intervals by the clinical team.The at-home tDCS option, administered by the patient following clinical guidance, is positioned by the company as a complementary pathway for individuals who require ongoing neuromodulation support between clinic vi...

This press release is issued by King Newswire